What is the 13F Pro Quality Score for BDTX?

13F Pro ranks Black Diamond Therapeutics, Inc. (BDTX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BDTX's current score at https://13fpro.ai/research/BDTX (free sign-up required for the full ranking).

Where does 13F Pro source BDTX data?

All Black Diamond Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Black Diamond Therapeutics, Inc. files with the SEC under CIK 1701541. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BDTX in?

Black Diamond Therapeutics, Inc. (BDTX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BDTX research updated on 13F Pro?

BDTX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Black Diamond Therapeutics, Inc.(BDTX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1701541 BDTX stock profile & AI dashboard →

13F Pro Quality Score

57.5/100

Rank #1,036 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

30.0/100

Profitability

93.5/100

Balance Sheet

96.5/100

Earnings Quality

30.0/100

Free Cash Flow

89.3/100

Institutional Flow

8.9/100

Revenue Scale

13.9/100

Dilution Risk

17.4/100

BDTX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Black Diamond Therapeutics, Inc. (BDTX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BDTX at 57.5/100 on a 32-signal composite quality model, placing it at rank #1,036 of 2,879 stocks — the top half of the AI-ranked universe. BDTX scores in the top quartile across balance sheet strength (96.5), profitability (93.5), free cash flow (89.3). Areas of concern include institutional flow (8.9) and revenue scale (13.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Black Diamond Therapeutics, Inc. reports net income of $-9.0M, free cash flow of $-10.2M. Top institutional holders of BDTX by reported 13-F value include NEA Management Company,, RENAISSANCE TECHNOLOGIES, DIMENSIONAL FUND ADVISORS, based on the most recent SEC filings. BDTX trades on the Nasdaq exchange and files with the SEC under CIK 1701541. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BDTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Black Diamond Therapeutics, Inc. directly from SEC EDGAR. Black Diamond Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 41 and 58 since 2026, currently 57.5 — an improving long-term trajectory across 8 quarterly and live scoring snapshots.

✦

Fun facts about Black Diamond Therapeutics, Inc.

Quirks, history, and lore behind BDTX — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Cambridge, Massachusetts · focused on oncology.
2
The Numbers
Like most clinical-stage biotechs, it carries no meaningful product revenue and burns cash on R&D — the balance sheet is essentially a countdown clock funded by equity raises.
3
The History
Founded around 2018, it was built on a scientific insight that most cancer drug programs had been targeting mutations the wrong way — chasing individual variants instead of the whole class.
4
The Secret
Its platform is called MAP — short for Mutation-Allostery-Pharmacology — designed to drug entire families of oncogenic mutations with a single compound rather than one mutation at a time.
5
The Lore
The company's name is a nod to its scientific ambition: targeting the hardest-to-reach, most stubborn mutations in cancer — the ones that, like a sheer rock face, everyone else said were unclimbable.
6
The Giveaway
Its ticker is BDTX, its lead programs target EGFR and RAS mutations, and its very name evokes the extreme sport of scaling black diamond-rated terrain — because curing cancer is not a bunny slope.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$0.00

Net Income

Q1 2026

$-9.0M

Free Cash Flow

Q1 2026

$-10.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$70.0MFY 2025

FY22 —FY23 —FY24 $0.00FY25 $70.0M

Net Income

+100.0% YoY

$22.4MFY 2025

FY22 $-91.2MFY23 $-82.4MFY24 $-69.68BFY25 $22.4M

Operating Income

+115.9% YoY

$12.5MFY 2025

FY22 $-92.8MFY23 $-86.5MFY24 $-78.8MFY25 $12.5M

EPS (Diluted)

+130.7% YoY

$0.39FY 2025

FY22 $-2.52FY23 $-1.88FY24 $-1.27FY25 $0.39

Total Assets

+16.6% YoY

$143.0MFY 2025

FY22 $156.3MFY23 $158.6MFY24 $122.6MFY25 $143.0M

Op. Cash Flow

+147.5% YoY

$29.6MFY 2025

FY22 $-85.1MFY23 $-66.7MFY24 $-62.3MFY25 $29.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2017
Revenue	$70.0M	$0.00	—	—	—	—
Net Income	$22.4M +100.0%	$-69.68B -84415.2%	$-82.4M +9.6%	$-91.2M +27.4%	$-125.6M	—
Operating Income	$12.5M +115.9%	$-78.8M +8.9%	$-86.5M +6.9%	$-92.8M +26.8%	$-126.9M	—
EPS (Diluted)	$0.39 +130.7%	$-1.27 +32.4%	$-1.88 +25.4%	$-2.52 +27.4%	$-3.47	—
Total Assets	$143.0M +16.6%	$122.6M -22.7%	$158.6M +1.5%	$156.3M -36.9%	$247.7M	—
Operating Cash Flow	$29.6M +147.5%	$-62.3M +6.6%	$-66.7M +21.6%	$-85.1M +15.0%	$-100.1M	—

AI Insight: BDTX Financial Trends

BDTX generated a one-time $70M revenue spike in Q1 2025 but returned to zero revenue with ongoing quarterly losses of $8-15M.

• Revenue jumped to $70M in Q1 2025 then dropped back to $0M for four consecutive quarters through Q1 2026.

• Net losses improved from $-20M in Q2 2024 to $-8M in Q3 2025 before worsening to $-15M in Q4 2025.

• Equity declined from $142M in Q1 2025 to $104M in Q1 2026, a $38M reduction over five quarters.

⚠ Operating cash flow turned negative again at $-10M in Q1 2026 after brief positive periods.

⚠ Equity burn rate averaging $7-8M per quarter since the Q1 2025 revenue event ended.

AI Insight: BDTX Ratio Trends

BDTX remains deeply unprofitable with ROE of -34.6% in Q1 2026, showing modest improvement from Q4 2025's -53.9%.

• ROE improved from -53.9% in Q4 2025 to -34.6% in Q1 2026, though still deeply negative.

• ROIC recovered from -62.8% in Q4 2025 to -43.2% in Q1 2026, continuing volatile pattern.

• Q1 2025 showed anomalous positive metrics with 77.9% operating margin and 159.8% ROE.

⚠ Persistent negative returns across all profitability metrics indicate ongoing cash burn concerns.

⚠ Quarter-to-quarter volatility in returns suggests unstable underlying business performance.

Get alerted when BDTX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Black Diamond Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BDTX

NEA Management Company, LLC
$9.5M4,448,757 sh
RENAISSANCE TECHNOLOGIES LLC
$3.5M1,643,747 sh
DIMENSIONAL FUND ADVISORS LP
$2.8M1,301,664 sh
BlackRock, Inc.
$2.4M1,106,840 sh
Connor, Clark & Lunn Investment Management Ltd.
$2.3M1,058,397 sh
MACKENZIE FINANCIAL CORP
$1.8M844,835 sh
MARSHALL WACE, LLP
$1.8M836,266 sh
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$1.8M834,570 sh
BRIDGEWAY CAPITAL MANAGEMENT, LLC
$1.5M723,477 sh
GOLDMAN SACHS GROUP INC
$1.5M684,418 sh

Fund	Value	Shares
NEA Management Company, LLC	$9.5M	4,448,757
RENAISSANCE TECHNOLOGIES LLC	$3.5M	1,643,747
DIMENSIONAL FUND ADVISORS LP	$2.8M	1,301,664
BlackRock, Inc.	$2.4M	1,106,840
Connor, Clark & Lunn Investment Management Ltd.	$2.3M	1,058,397
MACKENZIE FINANCIAL CORP	$1.8M	844,835
MARSHALL WACE, LLP	$1.8M	836,266
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	$1.8M	834,570
BRIDGEWAY CAPITAL MANAGEMENT, LLC	$1.5M	723,477
GOLDMAN SACHS GROUP INC	$1.5M	684,418

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BDTX on your watchlist

Track score changes the day Black Diamond Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BDTX a good stock to buy?

13F Pro's AI-powered analysis of Black Diamond Therapeutics, Inc. (BDTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BDTX are available on the BDTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BDTX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BDTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Black Diamond Therapeutics, Inc.'s investment landscape.